At Aplagon we are developing first-in-class therapeutic treatments, APACs, to manage unmet needs in vascular medicine.
APACs target a wide range of vascular injury related thromboinflammatory vessel occlusions, as well as preventing the consequences of reperfusion ischemia in the kidneys and heart.
Aplagon and Cadila Pharmaceuticals have entered into a clinical development and commercialization agreement for the lead APAC product in India.
Aplagon has signed an EIC Accelerator funding agreement with the European Innovation Council and SMEs Executive Agency (EISMEA) for the early clinical studies of APAC in advanced peripheral arterial occlusive disease / critical limb ischemia patients in Europe.
If you are interested in discussing partnering opportunities with Aplagon, please email: firstname.lastname@example.org